articleNature GeneticsApr 6, 2023HYBRID OA

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

ARArvind RaviMDMatthew D. HellmannMAMonica ArniellaMHMark HoltonSSSamuel S. Freeman

Broad Institute · Dana-Farber Cancer Institute · +25 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first joint analysis of the Stand Up To Cancer-Mark Foundation cohort, a resource of whole exome and/or RNA sequencing from 393 patients with NSCLC treated with anti-PD-(L)1 therapy, along with matched clinical response annotation. We identify a number of associations between molecular features and outcome, including (1) favorable (for example, ATM altered) and unfavorable (for example, TERT amplified) genomic subgroups, (2) a prominent association between expression of…

Citation impact

183
total citations
FWCI
39.83
Percentile
100%
References
110
Citations per year

Authors

42

Topics & keywords

Topics
Keywords
  • Biology
  • Blockade
  • Exome sequencing
  • Transcriptome
  • Lung cancer
  • Immune checkpoint
  • Computational biology
  • Immunotherapy
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding